Special Report: Creso Pharma has received the first orders for its innovative therapeutic lozenges from one of Australia’s leading medicinal cannabis companies.

It’s the latest big development for Creso Pharma (ASX:CPH), which has been on a roll as of late — the company pulled in nearly $1 million in revenue for the six months to June, a rise of over 400 per cent.

>> Learn more about Creso Pharma  

The order, for Creso’s cannaQIX 50 therapeutic cannabis lozenges, comes from Burleigh Heads Cannabis, which Creso partnered with back in May. The products will be sold in Australia under the name LozaCann, via Burleigh’s extensive distribution network.

The two companies have also agreed to explore further therapeutic, medicinal Creso products under the exclusive distribution deal.

The cannaQIX 50 lozenges are designed to help manage chronic pain. Each lozenge contains 50mg of cannabidiol as well as a range of vitamins. They dissolve in the mouth, which makes them more efficient — as well as more pleasing to the patient.

The cannaQIX 50 lozenges, to be sold via Burleigh Heads Cannabis’ distribution network as LozaCann.

“We are excited to provide Creso Pharma with an avenue to market which in turn provides Australian patients and doctors with another quality product option to utilise in patient care,” said Guy Headley, operations director at Burleigh.

Dr Miri Halperin Wernli, Creso CEO and co-founder, said the news was evidence of demand for Creso’s products ahead of its acquisition by Canadian pot stock PharmaCielo.

“We are happy to announce the first orders for cannaQIX 50 in Australia. Burleigh Heads Cannabis and CDA Clinics Australia continue to rapidly expand their patient reach with their extensive distribution network,” she said.

“This will provide a much-needed opportunity for patients to access our innovative products, and we are optimistic that this experience will support continued expansion to additional global markets.”


●      Subscribe to our daily newsletter

●      Join our small cap Facebook group

●      Follow us on Facebook or Twitter


This story was developed in collaboration with Creso Pharma, a Stockhead advertiser at the time of publishing.
This story does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.